Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESLA NASDAQ:GNTA NASDAQ:INTS NASDAQ:RNXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESLAEstrella Immunopharma$1.03+4.8%$1.24$0.78▼$3.15$44.33M0.85128,383 shs20,214 shsGNTAGenenta Science$1.80-0.6%$1.15$0.55▼$10.00$42.46M0.91.28 million shs260,633 shsINTSIntensity Therapeutics$4.03-1.7%$4.51$3.51▼$43.50$10.88M2.7844,435 shs33,150 shsRNXTRenovoRx$0.97+2.8%$0.89$0.70▼$1.45$43.75M1.01322,153 shs137,214 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESLAEstrella Immunopharma0.00%+4.84%-8.62%-3.30%+13.05%GNTAGenenta Science0.00%+7.74%+75.73%+187.30%-41.61%INTSIntensity Therapeutics0.00%+4.46%-6.72%-26.49%-48.97%RNXTRenovoRx0.00%+2.58%+3.77%-11.80%-26.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESLAEstrella Immunopharma$1.03+4.8%$1.24$0.78▼$3.15$44.33M0.85128,383 shs20,214 shsGNTAGenenta Science$1.80-0.6%$1.15$0.55▼$10.00$42.46M0.91.28 million shs260,633 shsINTSIntensity Therapeutics$4.03-1.7%$4.51$3.51▼$43.50$10.88M2.7844,435 shs33,150 shsRNXTRenovoRx$0.97+2.8%$0.89$0.70▼$1.45$43.75M1.01322,153 shs137,214 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESLAEstrella Immunopharma0.00%+4.84%-8.62%-3.30%+13.05%GNTAGenenta Science0.00%+7.74%+75.73%+187.30%-41.61%INTSIntensity Therapeutics0.00%+4.46%-6.72%-26.49%-48.97%RNXTRenovoRx0.00%+2.58%+3.77%-11.80%-26.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESLAEstrella Immunopharma 2.00Hold$8.00676.70% UpsideGNTAGenenta Science 1.00SellN/AN/AINTSIntensity Therapeutics 2.75Moderate Buy$37.50830.52% UpsideRNXTRenovoRx 2.75Moderate Buy$8.50776.29% UpsideCurrent Analyst Ratings BreakdownLatest INTS, GNTA, RNXT, and ESLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026GNTAGenenta Science Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/12/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/8/2026RNXTRenovoRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026RNXTRenovoRx Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.50 ➝ $14.005/28/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/20/2026INTSIntensity Therapeutics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSpeculative Buy5/14/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026INTSIntensity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/9/2026RNXTRenovoRx Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $13.504/8/2026RNXTRenovoRx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESLAEstrella ImmunopharmaN/AN/AN/AN/A($0.27) per shareN/AGNTAGenenta ScienceN/AN/AN/AN/A$1.29 per shareN/AINTSIntensity TherapeuticsN/AN/AN/AN/A$4.94 per shareN/ARNXTRenovoRx$1.12M39.06N/AN/A$0.15 per share6.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESLAEstrella Immunopharma-$13.06M-$0.34N/AN/AN/AN/AN/A-397.36%9/2/2026 (Estimated)GNTAGenenta Science-$7.39MN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)INTSIntensity Therapeutics-$11.61M-$5.71N/AN/AN/AN/A-136.82%-105.82%8/6/2026 (Estimated)RNXTRenovoRx-$11.17M-$0.33N/AN/AN/A-823.98%-135.03%-101.92%8/13/2026 (Estimated)Latest INTS, GNTA, RNXT, and ESLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ESLAEstrella Immunopharma-$0.0840-$0.05+$0.0340-$0.05N/AN/A5/14/2026Q1 2026RNXTRenovoRx-$0.08-$0.08N/A-$0.09$0.47 million$0.56 million5/7/2026Q1 2026INTSIntensity Therapeutics-$1.0850-$0.96+$0.1250-$0.96N/AN/A3/31/2026Q4 2025GNTAGenenta Science-$0.3641-$0.0750+$0.2891-$0.0750N/AN/A3/30/2026Q4 2025RNXTRenovoRx-$0.08-$0.08N/A-$0.08$0.42 million$0.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AINTSIntensity TherapeuticsN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESLAEstrella ImmunopharmaN/A0.240.24GNTAGenenta Science0.3514.1614.16INTSIntensity Therapeutics0.014.864.86RNXTRenovoRxN/A7.156.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESLAEstrella Immunopharma0.35%GNTAGenenta Science15.13%INTSIntensity Therapeutics3.74%RNXTRenovoRx3.10%Insider OwnershipCompanyInsider OwnershipESLAEstrella Immunopharma5.80%GNTAGenenta Science28.99%INTSIntensity Therapeutics7.60%RNXTRenovoRx9.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESLAEstrella ImmunopharmaN/A43.03 million40.54 millionNot OptionableGNTAGenenta Science723.59 million16.75 millionNot OptionableINTSIntensity Therapeutics2,0212.70 million2.50 millionNot OptionableRNXTRenovoRx645.10 million40.86 millionNot OptionableINTS, GNTA, RNXT, and ESLA HeadlinesRecent News About These CompaniesRenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 TranscriptJune 23, 2026 | seekingalpha.comRenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic CancerJune 11, 2026 | globenewswire.comAscendiant Remains a Buy on RenovoRx (RNXT)June 5, 2026 | theglobeandmail.comRenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rdJune 4, 2026 | globenewswire.comRenovoRx, Inc.: RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic CancerMay 28, 2026 | finanznachrichten.deRenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic CancerMay 28, 2026 | globenewswire.comRenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual MeetingMay 26, 2026 | globenewswire.comMark Voll Buys 25,000 Shares of RenovoRx (NASDAQ:RNXT) StockMay 22, 2026 | insidertrades.comRenovoRx (RNXT) Q1 2026 Earnings TranscriptMay 19, 2026 | fool.comRenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20thMay 19, 2026 | globenewswire.comShaun Bagai, CEO of Renovorx, buys $0 of RNXT stockMay 18, 2026 | investing.comRenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic ExpansionMay 15, 2026 | finance.yahoo.comRenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2026 | zacks.comRenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-QuarterMay 14, 2026 | finance.yahoo.comRenovoRx Inc (RNXT) Q1 2026 Earnings Report Preview: What To ExpectMay 14, 2026 | finance.yahoo.comRenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseMay 7, 2026 | zacks.comAnalysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA)May 1, 2026 | theglobeandmail.comRenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ETApril 29, 2026 | globenewswire.comRenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual MeetingApril 23, 2026 | globenewswire.comRenovoRx (RNXT) price target decreased by 15.63% to 6.88April 16, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Meta Unveils Subscriptions: A New Offering With Real Growth PotentialBy Leo Miller | June 8, 2026Frozen Assets: How Super Micro Puts AI Heat on IceBy Jeffrey Neal Johnson | June 24, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026INTS, GNTA, RNXT, and ESLA Company DescriptionsEstrella Immunopharma NASDAQ:ESLA$1.03 +0.05 (+4.80%) Closing price 04:00 PM EasternExtended Trading$1.01 -0.02 (-1.94%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Genenta Science NASDAQ:GNTA$1.80 -0.01 (-0.55%) Closing price 04:00 PM EasternExtended Trading$1.80 -0.01 (-0.28%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.Intensity Therapeutics NASDAQ:INTS$4.03 -0.07 (-1.71%) Closing price 04:00 PM EasternExtended Trading$4.00 -0.03 (-0.62%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.RenovoRx NASDAQ:RNXT$0.97 +0.03 (+2.79%) Closing price 04:00 PM EasternExtended Trading$0.97 +0.00 (+0.21%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
